Therapeutic efficacy of cyclophosphamide as a function of inhibition of its metabolism.
D000478:Alkylation; D000818:Animals; D001375:Azaguanine / Q000494:pharmacology; D001667:Binding, Competitive; D002279:Carcinoma 256, Walker / Q000188:drug therapy; D003520:Cyclophosphamide / Q000037:antagonists & inhibitors / Q000097:blood / Q000378:metabolism* / Q000627:therapeutic use / Q000633:toxicity; D003900:Desoxycorticosterone / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005260:Female; D012739:Gonadal Steroid Hormones / Q000494:pharmacology; D008297:Male; D008614:Meperidine / Q000494:pharmacology; D015122:Mercaptopurine / Q000494:pharmacology; D008797:Metyrapone / Q000494:pharmacology; D008862:Microsomes, Liver / Q000201:enzymology; D009020:Morphine / Q000494:pharmacology; D010615:Phenacetin / Q000494:pharmacology; D011335:Proadifen / Q000494:pharmacology; D011339:Probenecid / Q000494:pharmacology; D011803:Quinine / Q000494:pharmacology; D051381:Rats
D012739:Gonadal Steroid Hormones; D003900:Desoxycorticosterone; D009020:Morphine; D003520:Cyclophosphamide; D008614:Meperidine; D011335:Proadifen; D011803:Quinine; D015122:Mercaptopurine; D010615:Phenacetin; D011339:Probenecid; D001375:Azaguanine; D008797:Metyrapone